MultiplexDX proudly participated in the 48th San Antonio Breast Cancer Symposium (SABCS 2025), held December 9–12, 2025, in San Antonio, Texas, the world’s leading scientific conference dedicated to breast cancer research and translational oncology. The meeting brought together global experts in diagnostics, precision medicine, and breast cancer therapeutics to share the latest clinical and scientific advances.

Our team engaged with clinicians, researchers, and industry leaders to discuss the future of biomarker-driven treatment selection and next-generation molecular diagnostics. A key milestone for the company was the presence of the first-ever MultiplexDX exhibition booth at SABCS, representing an important step in strengthening our international visibility and expanding strategic partnerships within the global oncology community.

 During the symposium, MultiplexDX highlighted the clinical potential of Multiplex8+, our advanced molecular platform designed to improve breast cancer classification, predict treatment response, and support more personalized therapeutic decision-making. Our participation at SABCS 2025 further reinforces MultiplexDX’s commitment to translating cutting-edge science into clinically actionable solutions for patients worldwide.